Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171898 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
A Phase 1 study, sponsored by Aragon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT01171898 is a Phase 1 study that has completed, run by Aragon Pharmaceuticals. The registered enrollment target is 127 participants.
The verdict
NCT01171898, a Phase 1 study, has completed, sponsored by Aragon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.
Interventions
- DRUG ARN-509 (Phase 1)
- DRUG ARN-509 (Phase 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2010-07-26 |
| Est. Completion | 2025-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01171898
The ClinicalTrials.gov registry entry for NCT01171898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARN-509 (Phase 1) is the first listed.
NCT01171898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01171898 about?
NCT01171898 is a clinical study titled "Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)". The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of pat...
What is the current status of trial NCT01171898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2010-07-26. Estimated completion is 2025-07-22.
What interventions are being tested in trial NCT01171898?
The interventions under investigation include: ARN-509 (Phase 1) (DRUG), ARN-509 (Phase 2) (DRUG).
Who is sponsoring clinical trial NCT01171898?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.